Head & neck cancer
Anti-EGFR therapy and PD-1 blockade in recurrent/metastatic squamous-cell carcinoma.
- Trials
- 1
- Years
- 2019
Sort
- 2019KEYNOTE-048R/M HNSCCIn 882 patients with untreated recurrent or metastatic squamous-cell head and neck cancer, pembrolizumab or pembrolizumab + platinum + 5-FU improved overall survival compared with cetuximab + platinum + 5-FU (EXTREME).Read →